MedTrace Logo

Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

NCT01568021 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2015-02-10

Study results available
· View outcomes & findings →

Summary

This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.

Conditions

  • Retinal Vein Occlusion
  • Macular Edema

Interventions

OTHER

No Intervention

No intervention was administered in this study.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Denmark
  • Norway
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01568021 on ClinicalTrials.gov